SCHEDULE 13G/A: BlackRock Discloses 5.1% Stake in Enliven Therapeutics
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.1% beneficial ownership stake in Enliven Therapeutics Inc., held in the ordinary course of business.
Summary
- BlackRock, Inc. reported beneficial ownership of 2,941,395 shares of Enliven Therapeutics Inc. common stock.
- This represents 5.1% of the total outstanding common stock of Enliven Therapeutics Inc.
- BlackRock holds sole voting power over 2,885,529 shares and sole dispositive power over 2,941,395 shares.
- The shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
- The filing is an Amendment No. 1 to a previous Schedule 13G.
- The date of the event which required this filing is stated as June 30, 2025.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing disclosing an ownership stake, which is neutral in sentiment. It indicates a significant institutional holding but provides no performance or strategic updates.
Positives
- A significant institutional investor, BlackRock, holds a substantial stake, indicating confidence or inclusion in their investment portfolios.
- The stake is held in the ordinary course of business, suggesting a passive investment rather than an activist intent.
Future Outlook
The filing does not provide any forward-looking statements or guidance regarding Enliven Therapeutics Inc.'s future performance or strategic direction.
Industry Context
This filing represents a routine disclosure by a major institutional asset manager, BlackRock, regarding its passive investment stake in Enliven Therapeutics Inc. Such disclosures are common for large investment firms that cross beneficial ownership thresholds in publicly traded companies, reflecting their portfolio management activities rather than specific strategic moves related to the issuer's industry.
Stakeholder Impact
- Shareholders of Enliven Therapeutics Inc. may view BlackRock's significant stake as a positive signal of institutional interest and stability.
- The filing confirms BlackRock's role as a passive investor, not seeking to influence control of the issuer.
Key Dates
| Date | Description |
|---|---|
| 2025-01-21 | Date of execution for the Power of Attorney document. |
| 2025-06-30 | Date of event which required the filing of this statement. |
| 2025-07-17 | Date of filing of this Schedule 13G Amendment No. 1. |
Keywords
BlackRock, Enliven Therapeutics Inc., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, ELVN
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.